Iridium Q2 Results Fade as Rocket Lab Acquisition Takes Center Stage

What happened

Iridium reported Q2 2026 results, but the headline is the pending acquisition by Rocket Lab expected to close in mid-2027. The DeepValue report had flagged execution risks around Aireon integration, leverage, and EMSS renewal, assigning a WAIT rating at $51.40. That framework is now moot as the acquisition price will determine returns. Management likely emphasized steady operational trends to smooth the deal narrative, but the core business still faces leverage and revenue concentration challenges. The long closing timeline introduces execution risk, including regulatory hurdles and potential competing bids.

Implication

Investors should shift focus from operational catalysts to the acquisition terms: the implied price per share versus the current $51.40. The DeepValue report's downside scenarios ($32) are now less relevant if the deal closes, but the mid-2027 timeline means capital is locked for nearly a year with uncertainty. If the acquisition price is below intrinsic value (DeepValue base $50, bull $62), accept and tender; if above, consider selling into strength. Key risks: antitrust review, financing conditions, or a superior bid from another party. The EMSS renewal and Aireon integration become less critical for public shareholders but remain relevant for deal valuation.

Thesis delta

The investment thesis shifts from fundamental evaluation of Aireon integration and NTN Direct to a binary event: the Rocket Lab acquisition. The earlier WAIT rating was predicated on post-close leverage and subscriber data; now the key variable is the acquisition price and probability of completion. Investors no longer need to assess operational milestones—only the deal's fairness and likelihood of closing.